Highly Probable UK Approval of DCVax-L in 3Q, 2024 Would Be a Crowning Achievement for Northwest BiotherapeuticsWednesday, January 10, 2024 · 9:56 pm |
|
Presentation of DCVax-L Results from ASCO by Dr. Keyoumers AshkanMonday, June 6, 2022 · 7:28 am |
|
Northwest Biotherapeutics: Debunking Silly, Fictitious Adam Feuerstein Article Falsely Claiming Phase 3 Trial of DCVax-L in Glioblastoma Multiforme Was a FailureWednesday, May 25, 2022 · 8:57 am |
|
Presentation at the New York Academy of Sciences on Final Results of Phase 3 DCVax-L Trial Showing Impressive Efficacy (Part 3) Analyzing Hedge Fund Stock Manipulation TechniquesWednesday, May 11, 2022 · 3:07 pm |
|
Presentation at the New York Academy of Sciences on Final Results of DCVax-L Phase 3 Trial Showing Impressive Efficacy (Part 2) Incredibly Low p-Values on Median Overall Survival EndpointsTuesday, May 10, 2022 · 3:41 pm |
|
Presentation at the New York Academy of Sciences on Final Results of Phase 3 DCVax-L Trial Showing Impressive Efficacy (Part 1) Debunking Hedge Fund MisinformationTuesday, May 10, 2022 · 1:51 pm |
|
Northwest Biotherapeutics (NWBO, $0.86, Buy) Addressing Key Questions Relating to the Possible Approval and Commercialization of DCVax-L in Glioblastoma MultiformeWednesday, January 26, 2022 · 7:19 pm |
|
Northwest Biotherapeutics: FDA Statement Regarding Use of External Controls in Clinical Trials is a Huge PositiveFriday, January 21, 2022 · 8:18 am |
|
Northwest Biotherapeutics Issues Encouraging Update on Manufacturing Capabilities (NWBO, $1.59, Buy)Monday, March 22, 2021 · 6:21 am |
|
Northwest Biotherapeutics: Waiting for Top Line Data on DCVax-L (NWBO, $1.25 Buy)Friday, November 6, 2020 · 3:16 pm |
|
Northwest Biotherapeutics: Reason for Yesterday’s Stock Surge (NWBO, Buy, $1.12)Tuesday, October 13, 2020 · 8:44 am |
|
Northwest Biotherapeutics: Two Recent Press Releases Indicate that Manufacturing is on Track to Support Commercialization of DCVax-L (NWBO, Buy, $0.55)Friday, September 4, 2020 · 7:55 am |
|
Northwest Biotherapeutics: (NWBO, Buy, $0.35) Management Issues Guidance That DCVax-L Phase 3 Trial Results Will Be Released Sometime After Labor DayMonday, August 3, 2020 · 9:24 am |
|
Northwest Biotherapeutics: We Are Just Several Weeks from Release of Topline Data in Phase 3 Trial of DCVax-L in Newly Diagnosed Glioblastoma Multiforme (NWBO, $0.36, Buy)Monday, June 29, 2020 · 9:55 am |
|
Northwest Biotherapeutics (NWBO, Buy, $0.26) Detailed Results for the Phase 3, DCVax-L Trial in ndGBM Are ImminentFriday, May 22, 2020 · 12:09 pm |
|
Northwest Biotherapeutics: Why I Believe there is a High Probability for Approval of DCVax-L (NWBO, Buy, $0.21)Thursday, January 16, 2020 · 8:29 am |
|
Novocure: First Report on this Dynamic Growth Stock with Important Similarities to Northwest Biotherapeutics (NVCR, $78.77)Thursday, January 2, 2020 · 10:08 am |
|
Northwest Biotherapeutics: Company is Closing in on Unblinding of the Phase 3 Trial of DCVax-L in GBM That Could Lead to a Cascade of Important Follow-On Events (NWBO, Buy, $0.22)Thursday, November 21, 2019 · 7:42 am |
|
Northwest Biotherapeutics: Management’s Decision to Determine Survival Tail for DCVax-L in Phase 3 Trial in Newly Diagnosed Glioblastoma Was Absolutely the Right Move (NWBO, Buy, $0.25)Tuesday, September 17, 2019 · 11:22 am |
|
Northwest Biotherapeutics: Takeaways from Marnix Bosch’s Presentation at ASCO (NWBO, Buy, $0.27)Tuesday, June 4, 2019 · 10:38 am |
|
Northwest Biotherapeutics: Non-Dilutive Financing Provides Major Boost to Investment Outlook (NWBO, $0.25, Buy)Monday, December 17, 2018 · 3:18 pm |
|
Northwest Biotherapeutics: Blinded Data from DCVax®-L Phase 3 Trial is Extremely Encouraging, But We Still Need to See Unblinded Data (NWBO, Buy, $0.29)Monday, December 10, 2018 · 9:51 am |
|
Northwest Biotherapeutics: There could be Overwhelming Patient Demand for DCVax-L due to the Right to Try law (NWBO, $0.24, Buy)Wednesday, June 13, 2018 · 8:57 am |
|
Northwest Biotherapeutics; Five Spectacular Patient Outcomes for Patients Treated with DCVax-L as Reported at ASCO (NWBO, $0.28, Buy)Tuesday, June 5, 2018 · 12:29 pm |
|
Northwest Biotherapeutics: Right to Try Law Potentially Could Lead to Meaningful Revenues Prior to Formal Approval of DCVax-L (NWBO, Buy, $0.30)Sunday, June 3, 2018 · 1:30 pm |
|
Northwest Biotherapeutics: Blinded Data from Phase 3 Trial Strongly Suggests that DCVax-L is a Major Advance in the Treatment of Newly Diagnosed Glioblastoma Multiforme; It Looks Like NWBO Has Hit a Therapeutic and Commercial Home Run (NWBO, Buy, $0.25)Wednesday, May 30, 2018 · 9:10 am |
|
Northwest Biotherapeutics: How the Right to Try Remarks in President Trump State of the Union Could Favorably Affect Regulatory Action on DCVax-L and DCVax Direct (NWBO, Buy, $0.33)Wednesday, February 14, 2018 · 3:40 pm |
|
Northwest Biotherapeutics: Two Lead Investigators on DCVax-L Phase 3 Trial Believe That It Could be a Major Therapeutic Advance in Treating Glioblastoma Multiforme (NWBO, Buy, $0.29)Tuesday, January 9, 2018 · 11:28 am |
|
Northwest Biotherapeutics: Issues to Focus on in Pending Manuscript Dealing with Blinded Data from Phase 3 Trial of DCVax-L in Newly Diagnosed Glioblastoma (NWBO, Buy, $0.23)Thursday, January 4, 2018 · 10:41 am |
|
Northwest Biotherapeutics: Thoughts on Why the Phase 3 Trial of DCVax-L is Ongoing (NWBO, BUY, $0.17)Wednesday, September 13, 2017 · 10:46 am |
|
Northwest Biotherapeutics, Bristol-Myers Squibb: Success for the Yervoy-Opdivo Combination in CHECKMATE-214 Trial Obviously is a Major Positive for BMY, but also has Important Implications for NWBO (NWBO, Buy, $0.19) (BMY, $60.80, Buy)Thursday, September 7, 2017 · 9:56 am |
|
Northwest Biotehrpeutics: How Does DCVax-L Clinical Data Compare to the CAR-T Therapy Axi-Cel? (NWBO, $0.18, Buy)Friday, August 25, 2017 · 10:28 am |
|
Northwest Biotherapeutics: Why I Believe That the Phase 3 Trial of DCVax-L in Newly Diagnosed Glioblastoma Patients Has a Very Good Chance for Success (NWBO, Buy, $0.17)Friday, July 7, 2017 · 11:18 am |
|
Northwest Biotherapeutics: Is There Any Chance for DCVax-L to be Successful in the Phase 3 Trial? (NWBO, Buy, $0.24)Monday, March 27, 2017 · 3:45 pm |
|
Northwest Biotherapeutics and Agenus: What Are The Implications for These Companies in the Aftermath of Two Recent Cancer Vaccine Trial Failures? (NWBO, $0.38, Buy) (AGEN, $3.99, Buy)Monday, February 27, 2017 · 12:10 pm |
|
Northwest Biotherapeutics: 8-K Document Released Today Provides New and Very Interesting Data on Patients Treated with DCVax-L. (NWBO, Buy, $0.48)Wednesday, February 8, 2017 · 4:06 pm |
|
Northwest Biotherapeutics: Partial Clinical Hold on Phase 3 Trial of DCVax-L in Newly Diagnosed Glioblastoma is Lifted (NWBO, Buy, $0.45)Tuesday, February 7, 2017 · 3:06 pm |
|
SmithOnStocks Top Stock Picks for 2017, January 3, 2017Tuesday, January 3, 2017 · 10:18 am |
|
Northwest Biotherapeutics: DCVax-L Viewed Through the Eyes of Dr. Linda Liau, Lead Investigator on the Phase 3 Trial of DCVax-L (NWBO, $0.35, Buy)Wednesday, December 21, 2016 · 4:46 pm |
|
Northwest Biotherapeutics: Phase 2 Trial in Colorectal Cancer with Liver Metastases Announced (NWBO, Buy, $0.55)Thursday, November 17, 2016 · 9:57 am |
|
Northwest Biotherapeutics: Recent Data Update on Phase 1/2 Trial of DCVax Direct is Encouraging (NWBO, Speculative Buy, $0.43)Sunday, October 9, 2016 · 9:46 am |
|
Northwest Biotherapeutics: My Hypothesis as to Why the Company Has Been Silent on Its Clinical Trial Programs and Why DCVax-L Might Succeed in its Phase 3 Trial (NWBO, Speculative Buy, $0.34)Thursday, September 8, 2016 · 3:25 pm |
|
Northwest Biotherapeutics: Going Over My Thoughts (NWBO, $0.62)Monday, June 20, 2016 · 9:35 am |
|
Northwest Biotherapeutics: The Company Provides an Operations Update (NWBO, $1.23)Thursday, May 5, 2016 · 9:29 am |
|
Northwest Biotherapeutics: A Comprehensive Evaluation of Its Lead Product DCVax-L (NWBO, $1.50)Tuesday, March 22, 2016 · 1:32 pm |
|
Northwest Biotherapeutics: Why the Failure of Celldex’s Rintega in Newly Diagnosed Glioblastoma Probably Has No Implications for the DCVax-L TrialFriday, March 11, 2016 · 8:35 am |
|
Northwest Biotherapeutics: Seeking Alpha Publishes Latest in a String of Attack Articles Authored by Short Sellers (NWBO, $4.92)Thursday, October 29, 2015 · 10:24 am |
|
Northwest Biotherapeutics: New Financing from Woodford was Much Needed (NWBO, $5.44)Wednesday, October 21, 2015 · 2:27 pm |
|
Northwest: Analysis of a Coordinated Short Selling Attack Against the Stock (NWBO, $4.69)Tuesday, October 20, 2015 · 12:36 pm |
|
Northwest Biotherapeutics: My Thoughts on the New Data from the Phase 1/2 Trial of DCVax Direct (NWBO, Buy, $6.91)Monday, September 28, 2015 · 9:00 am |
|
Northwest Biotherapeutics: Thoughts on Suspension of Screening of New Patients in the Phase 3 DCVax-L TrialTuesday, September 8, 2015 · 8:25 am |
|
Observations from ASCO on Immuno-oncology with a Focus on Northwest Biotherapeutics’ (NWBO, Buy, $9.43) DC-Vax-Direct© and the Checkpoint Inhibitors of Bristol-Myers Squibb and MerckMonday, June 8, 2015 · 8:35 am |
|
Northwest Biotherapeutics: FDA Panel Recommendation to Approve Amgen’s Cancer Vaccine is Hugely Significant In Regard to Possible Approval of DCVax-L and DCVax Direct. (NWBO, $7.86, Buy)Friday, May 1, 2015 · 11:42 am |
|
CAR-T Companies-Kite (KITE, $55.09) and Juno (JUNO, $47.30): Is The Bloom Coming Off The Rose? Are Investor Expectations Unrealistic?Wednesday, April 29, 2015 · 8:57 am |
|
Northwest Biotherapeutics: Comments on Two AACR Posters (NWBO, $8.62, Buy)Wednesday, April 15, 2015 · 1:18 pm |
|
Northwest Biotherapeutics: The $40 Million Woodford Financing is A Major Positive (NWBO, Buy, $7.76)Friday, April 3, 2015 · 2:37 pm |
|
Northwest Biotherapeutics: Still Another Rebuttal to a Feuerstein Attack Is Called ForFriday, April 3, 2015 · 8:33 am |
|
Northwest Biotherapeutics: Promising New Data Was Just Presented on DCVax-L in Recurrent Glioblastoma Multiforme (NWBO, Buy)Friday, March 27, 2015 · 9:27 am |
|
Northwest Biotherapeutics: How Much Will It Cost to Manufacture DCVax-L (NWBO, Buy, $7.26)Thursday, March 5, 2015 · 10:02 am |
|
The Potentially Key Role of Northwest Biotherapeutics in the Emerging Immuno-Oncology Landscape (NWBO, Buy, $6.19)Tuesday, February 3, 2015 · 9:01 am |
|
Notes from Linda Powers Presentation in San Francisco, January 12, 2015 (NWBO, Buy, $6.00)Tuesday, January 13, 2015 · 8:53 am |
|
Northwest Biotherapeutics: Putting Recent Clinical Data on DCVax Direct in Perspective (NWBO, Buy, $5.37)Friday, November 28, 2014 · 12:31 pm |
|
Northwest Biotherapeutics: Exciting News on Potential for Early Patient Access for DCVax-L in the UKWednesday, September 17, 2014 · 1:25 pm |
|
Northwest Biotherapeutics: National Geographic Special Features DCVax Direct Treatment of Stage 4 Pancreatic Cancer Patient (NWBO, Buy, $5.90)Monday, September 8, 2014 · 9:47 am |
|
Northwest Biotherapeutics: Independent Chairman of the DMC Committee for DCVax-L Phase 3 Trial Chastises Adam Feuerstein for Inaccurate Articles (NWBO, Buy, $6.43)Wednesday, August 13, 2014 · 12:00 pm |
|
CREW Alleges That Adam Feuerstein is Involved in Stock Manipulation Scheme in Regard to Northwest BiotherapeuticsWednesday, July 30, 2014 · 10:18 am |
|
Northwest Biotherapeutics: Market Research Firm Evaluate Pharma Projects 2020 Worldwide Sales of $2.0 billion for DCVax-L (NWBO, Buy, $5.92)Thursday, July 17, 2014 · 11:35 am |
|
Northwest Biotherapeutics: The Investment Tide May be Turning Positive (NWBO, Buy, $6.41, free content)Thursday, June 12, 2014 · 9:02 am |
|
Linda Powers, CEO of Northwest Biotherapeutics, Attacks and Debunks the Weak Bear Case in a Presentation on March 27Friday, March 28, 2014 · 7:15 am |
|
The BIO CEO Conference: Highlights from the Meeting and New Investment Perspectives (Subscribers Only)Friday, February 14, 2014 · 4:28 pm |
|
San Francisco Trip Is the Basis for a Preview of 2014 (Subscribers Only)Wednesday, January 22, 2014 · 3:48 pm |
|
Northwest Biotherapeutics: An Analysis of Its Transforming Balance Sheet Restructuring (NWBO, $4.14)Monday, December 9, 2013 · 9:42 am |
|
Northwest Biotherapeutics: Moving DC Vax-L Rapidly Forward and Starting DC Vax Direct Trials (NWBO, $3.63)Tuesday, May 7, 2013 · 12:44 pm |
|
Northwest Biotherapeutics: My Rationale for Having a Buy Recommendation (NWBO; $3.29)Monday, February 25, 2013 · 11:47 am |
|
Northwest Biotherapeutics: A Critique of Adam Feuerstein of TheStreet's Recent Analysis (NWBO, $3.50)Tuesday, February 19, 2013 · 9:52 am |
|
Northwest Biotherapeutics: Transformed from an Ugly Duckling Bulletin Board Company to a Promising NASDAQ Company (NWBO, $3.20)Monday, January 14, 2013 · 12:55 pm |
|
Northwest Biotherapeutics and ImmunoCellular Therapeutics Can Both Be Winners with their Cancer Vaccines (NWBOD, $5.50)Friday, September 28, 2012 · 10:10 am |
|
Northwest Biotherapeutics’ DCVax Cancer Vaccines May Be a Game Changer In Cancer Therapy (NWBO, $0.22)Thursday, July 19, 2012 · 10:54 am |
|
The Rationale Behind Dendritic Cell-Based Cancer Vaccines and How They are Manufactured (NWBO.OB, $0.22)Thursday, April 26, 2012 · 6:24 am |
|
|
There are 79 reports on file. |
